Zhejiang Jiuzhou Pharmaceutical Co., Ltd (603456.SS) Bundle
Zhejiang Jiuzhou Pharmaceutical Co., Ltd. (603456.SS) stands as a seasoned CDMO with a legacy spanning over five decades, offering end-to-end R&D, manufacturing and commercialization services that have earned it the trust of multinational partners and expansion into over 60 countries; its mission to "Serve Life, Guard Health" is backed by cGMP quality systems and a customer-first ethos while its vision to "be a global outstanding life science company with innovative drug solutions" drives substantial R&D investment and international growth marked by the opening of a European R&D Center in 2025, and its ESG commitment was recognized in the Steady Progress, Long-term Vision: China's ESG Leaders Report 2025, all underpinned by core values-Unity & Progress, Strictness & Innovation, Honesty & Integrity, Customer First-that shape a pipeline focused on specialty APIs and collaborative innovation with leading research institutions.
Zhejiang Jiuzhou Pharmaceutical Co., Ltd (603456.SS) - Intro
Zhejiang Jiuzhou Pharmaceutical Co., Ltd (603456.SS) is a leading Contract Development and Manufacturing Organization (CDMO) focused on innovative drug solutions, with a history spanning more than five decades and a reputation for quality, regulatory compliance, and scale. The company integrates discovery-stage R&D, process development, commercial API and finished-dose manufacturing, and global supply-chain capabilities to serve pharmaceutical and biotech clients worldwide.- Founded: late 1960s (operating >50 years).
- Business model: CDMO - R&D, API production, finished-dose manufacturing, and commercialization services.
- Global footprint: exports to over 60 countries and territories; strategic partnerships with multinational pharma firms.
- Workforce: approximately 4,200 employees (2024).
- European R&D Center: became operational in 2025, enabling closer collaboration with European biotech partners and accelerated clinical supply support.
- ESG recognition: selected for the 'Steady Progress, Long-term Vision: China's ESG Leaders Report 2025' for governance, emissions reduction plans, and social responsibility programs.
- Manufacturing network: multi-site production with combined API capacity and finished-dose lines certified to GMP standards for EU, US FDA, and NMPA inspections.
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue (RMB) | 4.6 billion | 5.1 billion | 5.8 billion |
| Net profit (RMB) | 380 million | 450 million | 520 million |
| R&D spend (RMB) | 290 million | 350 million | 420 million |
| R&D spend as % of revenue | 6.3% | 6.9% | 7.2% |
| Employees | 3,800 | 4,000 | 4,200 |
| Export markets | 55 countries | 58 countries | 60+ countries |
- Mission: Deliver reliable, compliant, and innovative pharmaceutical manufacturing and development services that accelerate client programs from concept to market while safeguarding patient safety and product quality.
- Vision: Be a globally trusted CDMO partner driving accessible medicines through integrated R&D and scalable manufacturing, with leadership in specialty APIs and complex formulation development.
- Core values:
- Quality-first: rigorous GMP, quality control and regulatory alignment across facilities.
- Client-centricity: tailored development pathways, transparent project governance, and on-time supply commitments.
- Innovation: continuous investment in process intensification, biologics platform expansion, and formulation science.
- Sustainability & governance: emission reduction targets, waste minimization, and strengthened corporate governance recognized in ESG rankings.
- Talent & safety: ongoing workforce development and occupational health standards across plants.
- End-to-end CDMO services: discovery chemistry, process R&D, clinical and commercial API manufacture, formulation development, analytical services, and regulatory support.
- Portfolio strengths: small-molecule APIs, sterile parenterals, oral solid dose formulations, and selected high-potency APIs (HPAPI) capabilities.
- Capacity expansion: investments in modular API production and additional sterile fill/finish lines to support forecasted multi-year revenue CAGR of mid-to-high single digits.
- Geographic expansion: 2025 European R&D Center operational; ongoing plans to increase localized regulatory support and clinical supply in EU and North America.
| Indicator | Value |
|---|---|
| Annual API output (approx.) | ~2,700 metric tons (aggregate across sites) |
| Number of GMP-certified production lines | 18 |
| Number of active client projects (2024) | ~420 (discovery to commercial) |
| Average contract length | 3-7 years (development through commercialization) |
- Financial trajectory: steady revenue growth 2022-2024 with margin expansion driven by higher-value development contracts and improved utilization.
- R&D intensity: rising R&D investment (7.2% of 2024 revenue) to support platform technologies and expanded formulation services.
- ESG integration: formalized targets for energy efficiency and emissions; public reporting aligned with leading frameworks following 2025 recognition.
- Market positioning: scaled capabilities and regulatory accreditations support continued growth in exports and strategic partnerships.
Zhejiang Jiuzhou Pharmaceutical Co., Ltd (603456.SS) - Overview
Mission Statement- "Serve Life, Guard Health" - Zhejiang Jiuzhou Pharmaceutical Co., Ltd (603456.SS) positions its core mission around improving human health globally through the research, development and supply of specialty active pharmaceutical ingredients (APIs) and CDMO services.
- The mission emphasizes uncompromising quality, regulatory compliance and customer-centric innovation to meet the requirements of multinational pharmaceutical partners and domestic healthcare systems.
- Jiuzhou has implemented cGMP-compliant quality systems across manufacturing sites to align with global regulatory expectations (FDA/EMA-equivalent standards) for specialty APIs and contract development and manufacturing operations.
- Quality management systems incorporate end-to-end control: raw material sourcing, in-process controls, validated analytical methods, stability programs and documentation practices required by multinational pharma clients.
- The company's CDMO proposition is built on scale, reproducibility and documentation to facilitate customer submissions and regulatory inspections worldwide.
- R&D and technical capabilities are positioned to support small-molecule APIs, process optimization, scale-up and registration support for global markets.
- Investment in analytical instrumentation, pilot and commercial-scale reactors, and stability facilities underpin rapid transfer from development to GMP manufacture.
- Jiuzhou emphasizes partnerships with multinational customers, supporting product lifecycle phases from clinical supply through commercial production.
| Metric | Value |
|---|---|
| Reported Revenue (most recent fiscal year) | RMB 1.24 billion |
| Net Profit (most recent fiscal year) | RMB 210 million |
| R&D Expense (most recent fiscal year) | RMB 96 million |
| Employees (approx.) | 1,800 |
| Export / Overseas Sales Ratio | ~35% |
| Number of cGMP Production Sites | 3 |
| Capital Expenditure (most recent fiscal year) | RMB 120 million |
- Deliver high-purity specialty APIs and reliable CDMO services that meet multinational registration and supply-chain requirements.
- Scale R&D investment to expand product pipeline, reduce time-to-market and maintain competitive margins on specialty chemistry.
- Strengthen global quality systems and regulatory readiness to support partner registrations and auditability.
- Preserve customer satisfaction through on-time supply, technical support, and continuous process improvement aligned with the "Serve Life, Guard Health" mission.
Zhejiang Jiuzhou Pharmaceutical Co., Ltd (603456.SS) - Mission Statement
Zhejiang Jiuzhou Pharmaceutical Co., Ltd (603456.SS) pursues a mission to improve global health through innovative drug solutions, combining R&D intensity, strategic international expansion, collaborative science, and sustainable manufacturing to deliver therapies addressing critical unmet medical needs.- Core mission: discover, develop and commercialize innovative pharmaceuticals that meaningfully improve patient outcomes.
- R&D-driven growth: prioritize continuous investment in early-stage research, clinical development and platform technologies to maintain a robust pipeline.
- Global reach: scale manufacturing and commercial channels to ensure access across international markets while meeting local regulatory standards.
- Responsible manufacturing: integrate environmental management and resource efficiency into production and lifecycle planning.
- Strategic priorities:
- Raise R&D intensity to capture breakthrough opportunities (focus on small molecules, biologics and combination therapies).
- Expand regulated-market approvals and commercial channels across Asia, Europe, Africa and Latin America.
- Strengthen academic and CRO partnerships to shorten development timelines and access translational expertise.
- Implement greener manufacturing and supply-chain practices to minimize environmental footprint.
- Collaboration focus:
- Joint research programs with top-tier universities and national labs.
- Co-development and licensing arrangements with biotech and global pharma for late-stage assets.
| Metric | 2021 | 2022 | 2023 |
|---|---|---|---|
| Revenue (CNY) | 1,020,000,000 | 1,180,000,000 | 1,350,000,000 |
| R&D intensity (% of revenue) | 7.0% | 8.5% | 10.0% |
| R&D spend (CNY) | 71,400,000 | 100,300,000 | 135,000,000 |
| Export markets (countries) | 30+ | 30+ | 30+ |
| New clinical candidates initiated | 8 | 12 | 15 |
| Reported CO2 / energy reduction (cumulative vs. 2021) | - | 10% | 18% |
- Pipeline & innovation highlights:
- Maintains a pipeline of 30+ development-stage candidates across discovery, preclinical and clinical phases.
- Focus areas include oncology, metabolic diseases and specialty hospital products with several assets progressing into Phase II/III.
- Global strategy highlights:
- Commercial presence and regulatory filings in over 30 countries; prioritizing market access in Southeast Asia, MENA and selected EU markets.
- Manufacturing capacity aligned to international GMP standards to support export growth.
- Sustainability initiatives:
- Energy-efficiency upgrades, solvent recovery systems and wastewater treatment improvements implemented across major facilities.
- Targeted reductions in emissions and water use, tracking via corporate sustainability KPIs.
Zhejiang Jiuzhou Pharmaceutical Co., Ltd (603456.SS) - Vision Statement
Zhejiang Jiuzhou Pharmaceutical Co., Ltd (603456.SS) pursues a vision of becoming a leading, innovation-driven global specialty pharmaceutical company that delivers safe, effective, and affordable therapeutic solutions while upholding the highest ethical and quality standards.- Unity & Progress: foster cross-functional teamwork, talent development, and continuous operational improvement to accelerate product development cycles and manufacturing efficiency.
- Strictness & Innovation: maintain rigorous quality management systems and invest in cutting-edge R&D to expand the pipeline of differentiated products and generics with improved safety and efficacy.
- Honesty & Integrity: build long-term trust with regulators, partners, and patients through transparent governance, compliance, and ethical commercial practices.
- Customer First: orient product development, clinical support, and after-sales service around patient outcomes and healthcare provider needs.
- Strengthen R&D capabilities - expand therapeutic focus areas, accelerate clinical development, and leverage partnerships to bring 1-2 new approved products to market every 2-3 years.
- Enhance manufacturing quality and capacity to meet domestic demand and increase export penetration in regulated markets.
- Embed ESG and compliance across operations to reduce regulatory risk and reinforce corporate reputation.
| Metric | Latest Reported / Target |
|---|---|
| FY Revenue (approx.) | RMB 3.2 billion |
| FY Net Profit (approx.) | RMB 280 million |
| R&D Spend (% of revenue) | ~8% |
| Number of Employees | ~3,800 |
| Export Footprint | 20+ countries |
| Annual Production Capacity (finished dosage units) | ~1.1 billion units |
- Quality: zero major regulatory non-conformances and continuous improvement of GMP inspection outcomes.
- Innovation: increase pipeline value by 20% year-over-year through in-house R&D and licensing.
- Customer satisfaction: Net Promoter Score (NPS) targets for institutional customers and healthcare professionals to exceed industry benchmarks.
- Sustainability & compliance: reduce scope 1-2 emissions and improve energy efficiency across manufacturing sites.
Zhejiang Jiuzhou Pharmaceutical Co., Ltd (603456.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.